Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

20

Revenue 2017

Astellas

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Astellas' 2013 sales performance.

Astellas Pharma Inc.

PM Society announces 2023 Digital Award winners

PM Society announces 2023 Digital Award winners

OPEN Health takes three Golds while Astellas Pharma UK tops client leader board. ... On the client side, the most successful company was Astellas Pharma UK, taking home two Golds and a Silver.

Pfizer and Astellas’ Xtandi granted FDA priority review for new prostate cancer indication

Pfizer and Astellas’ Xtandi granted FDA priority review for new prostate cancer indication Pfizer and Astellas have announced that their androgen receptor signalling inhibitor, Xtandi (enzalutamide), has been granted priority review by the US Food and Drug Administration (FDA) to treat patients with ... Ahsan Arozullah, senior vice president

Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

Astellas invests $50m to support advancement of Poseida’s cancer cell therapy Astellas Pharma and Poseida Therapeutics have announced a strategic investment to support Poseida’s commitment to redefining cancer cell therapy. ... with Astellas to advance our shared vision and explore future opportunities for collaboration to

Astellas and PeptiDream announce protein degrader research collaboration

Astellas and PeptiDream announce protein degrader research collaboration Chief strategy officer at Astellas, Adam Pearson, said: "Targeted protein degradation is one of the primary focuses of Astellas. ... Astellas will provide PeptiDream with an upfront payment of $21m, with PeptiDream eligible to receive around $146m in

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics The deal comes just less than a month after Astellas and Cullgen entered into a research collaboration and exclusive option agreement aimed at advancing targeted protein degraders. ... The partnership, which is worth up to $1.9bn, will utilise

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....